Moreover, while CD371+ is associated with good long-term outcomes in B-ALL, almost all DUX4-r cases show strong expression of this antigen, so it cannot be used to assess outcomes between DUX4-r cases. Here, DUX4 is linked to precursor B-cell acute lymphoblastic leukemia.